<HTML>
<HEAD>
<TITLE>Filed by Bowne Pure Compliance</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: Arial,sans-serif">
<DIV style="font-size: 10pt">
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): September 11, 2008</B>


<P style="font-size: 24pt" align="center"><B>AMICUS THERAPEUTICS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>001-33497</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>71-0869350</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>6 Cedar Brook Drive,
Cranbury, NJ<BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>08512</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(609) 662-2000</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV
style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV
style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: Arial,sans-serif">

<P style="font-size: 10pt" align="left"><B>&nbsp;</B>

<P style="font-size: 10pt" align="left"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement.</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">On
September&nbsp;11, 2008, Amicus Therapeutics, Inc. (&#8220;Amicus&#8221;), as
Lessee, and AG/Touchstone TP, LLC (&#8220;A/G Touchstone&#8221;), as Lessor,
entered into a lease agreement (the &#8220;Lease&#8221;) pursuant to which
Amicus will lease from AG/Touchstone approximately 7,668 square feet of
laboratory space for a small scale research facility in San Diego,
California (the &#8220;Premises&#8221;). The term of the Lease runs for three
years and may be extended by Amicus for an additional three-year term, subject
generally to agreement with A/G Touchstone on the fair market value of the rent
to be paid during such additional period. Amicus will pay monthly base rent of
$22,620, $23,299 and $23,998, respectively, in each of the first three years of
the Lease along with a proportional share of AG/Touchstone&#8217;s monthly
operating expenses, including real property taxes, for the building containing
the Premises, subject to customary exceptions. The Lease may be earlier
terminated by AG/Touchstone in the event that Amicus breaches the terms of the
Lease and fails to cure such breach within the applicable cure period and under
certain circumstances by Amicus in the event the Premises is damaged.

<P style="font-size: 10pt; text-indent: 4%; margin-right: 3%"
align="left">The San Diego facility will be utilized primarily to
support research into new applications of
Amicus&#8217; pharmacological chaperone technology for the treatment of
diseases with high unmet medical needs and larger patient populations, particularly in the areas of neurodegenerative and
metabolic disorders. A copy of the press release announcing the opening of
Amicus&#8217; San Diego facility is attached hereto as Exhibit&nbsp;99.1.

<P style="font-size: 10pt" align="left"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>

<P style="font-size: 10pt; text-indent: 4%"
align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp; <U>Exhibits .</U>

<P style="font-size: 10pt; text-indent: 8%" align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.1
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Release, dated September&nbsp;15, 2008.

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">2

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: Arial,sans-serif">

<P style="font-size: 10pt" align="left"><B>&nbsp;</B>

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; margin-left: 2%; text-indent: 2%; margin-right: 3%"
align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="50%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="3%">&nbsp;</TD>
  <TD width="2%">&nbsp;</TD>
  <TD width="45%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left" colspan="3">AMICUS THERAPEUTICS, INC.</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">Date: September&nbsp;15,
2008&nbsp; </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">By:&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">/s/ GEOFFREY P. GILMORE &nbsp;</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Name:&nbsp; </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Geoffrey P. Gilmore&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Title: </TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Senior Vice President and General
Counsel&nbsp;</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">3

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="margin-left: 0.25in; width: 7.2in; font-family: Arial,sans-serif">

<P style="font-size: 10pt" align="left"><B>&nbsp;</B>

<P style="font-size: 10pt; margin-left: 2%; margin-right: 3%"
align="left"><B>&nbsp;</B>

<P style="font-size: 10pt" align="center"><B>EXHIBIT INDEX</B>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">Exhibit&nbsp;No. </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Description</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release, dated September&nbsp;15,
2008</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c75294e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 12517}]
{"company-data": {"conformed-name": "AMICUS THERAPEUTICS INC", "cik": "0001178879", "assigned-sic": "2834", "irs-number": "200422823", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33497", "film-number": "081072195"}, "business-address": {"street1": "6 CEDAR BROOK DRIVE", "city": "CRANBURY", "state": "NJ", "zip": "08512", "phone": "(609) 662-2000"}, "mail-address": {"street1": "6 CEDAR BROOK DRIVE", "city": "CRANBURY", "state": "NJ", "zip": "08512"}}
Filed by Bowne Pure Compliance
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): September 11, 2008
AMICUS THERAPEUTICS,
INC.
(Exact name of registrant as
specified in its charter)
Delaware
001-33497
71-0869350
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
6 Cedar Brook Drive,
Cranbury, NJ
08512
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number,
including area code:
(609) 662-2000
(Former name or former address if changed since last report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On
September 11, 2008, Amicus Therapeutics, Inc. ("Amicus"), as
Lessee, and AG/Touchstone TP, LLC ("A/G Touchstone"), as Lessor,
entered into a lease agreement (the "Lease") pursuant to which
Amicus will lease from AG/Touchstone approximately 7,668 square feet of
laboratory space for a small scale research facility in San Diego,
California (the "Premises"). The term of the Lease runs for three
years and may be extended by Amicus for an additional three-year term, subject
generally to agreement with A/G Touchstone on the fair market value of the rent
to be paid during such additional period. Amicus will pay monthly base rent of
$22,620, $23,299 and $23,998, respectively, in each of the first three years of
the Lease along with a proportional share of AG/Touchstone's monthly
operating expenses, including real property taxes, for the building containing
the Premises, subject to customary exceptions. The Lease may be earlier
terminated by AG/Touchstone in the event that Amicus breaches the terms of the
Lease and fails to cure such breach within the applicable cure period and under
certain circumstances by Amicus in the event the Premises is damaged.
The San Diego facility will be utilized primarily to
support research into new applications of
Amicus' pharmacological chaperone technology for the treatment of
diseases with high unmet medical needs and larger patient populations, particularly in the areas of neurodegenerative and
metabolic disorders. A copy of the press release announcing the opening of
Amicus' San Diego facility is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(c)
Exhibits .
99.1
     Press Release, dated September 15, 2008.
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
AMICUS THERAPEUTICS, INC.
Date: September 15,
2008
By:
/s/ GEOFFREY P. GILMORE
Name:
Geoffrey P. Gilmore
Title:
Senior Vice President and General
Counsel
3
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release, dated September 15,
2008